Purpose Ovarian cancer is the leading cause of death among all gynecological malignancies in Western countries. Although therapy for ovarian cancer has been greatly improved in the past 20 years, the overall survival for patients with advanced ovarian cancer has not changed signiWcantly. The poor survival rates in patients with advanced ovarian cancer are due both to late diagnosis and to lack of eVective drugs for the majority of patients who have a relapse and develop resistance to current chemotherapy agents used for ovarian cancer. Thus, developing and discovering eVective novel drugs with diVerent molecular structures from conventional chemotherapy agents have become an urgent clinical need.
Introduction
Ovarian cancer is the leading cause of death among gynecological malignancies in the Western countries and aVects nearly 1 in 70 women aged 50-70 years [1] . According to the American Cancer Society, approximately 21,650 women will be diagnosed with ovarian cancer, and over 15,520 will die from this disease in 2008, in the United States [2] . Ovarian cancer has the highest mortality of all cancers associated with the female reproductive system, which reXects, in part, a lack of early symptoms and the associated diYculty of early detection. Thus, ovarian cancer is often diagnosed at an advanced stage. Most patients with ovarian cancer at an advanced stage are treated with cytoreductive surgery, followed by combination chemotherapy. Although an initial complete clinical response to chemotherapy is seen in 70% of patients, the majority of these patients will experience recurrence of the disease within 2 years and the 5-year survival rates are approximately 20-25% [3] . The Wrst-line chemotherapy drugs approved by the Food and Drug Administration (FDA) for advanced ovarian cancer include platinum-containing drugs, such as cisplatin and carboplatin. These drugs as well as paclitaxel, a taxane compound, are classiWed as anti-microtubular agents. Other agents, including hexamethylmelamine, topotecan, and pegylated liposomal doxorubicin, are used as second-line chemotherapy [4, 5] . However, patients with recurrent ovarian cancer usually develop resistance to these drugs. Therefore, development and discovery of new drugs capable of prolonging survival either by increasing long-term remission rates and/or duration of eVective Wrst-line treatment or to augment the eYcacy of second-line treatment have become an urgent clinical need.
The statin drug family has been used successfully in the treatment of hypercholesterolemia for more than a decade. To date, they are still the most powerful drugs for lowering cholesterol levels in blood [6] [7] [8] . In recent years, statins have been considered as potent candidates for treating malignant diseases including acute myelogenous leukemia, lymphoma, squamous cell carcinomas, colorectal cancer, breast cancer and melanoma. The anticancer function of statins is based on preclinical evidence of their antiproliferative, pro-apoptotic and anti-invasive properties. Statins can induce apoptosis and inhibit proliferation in a variety of cancer cell types [9] [10] [11] [12] [13] . In vivo studies have revealed that statins can inhibit tumor cell growth, invasion and metastasis [14] [15] [16] . In addition, statins sensitize cancer cells to chemotherapy drugs [17] [18] [19] . Lovastatin treatment enhances the antitumor activity of doxorubicin, a common chemotherapeutic agent for a wide range of cancer [20] . A combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells [21] .
Statins are inhibitors of HMG-CoA reductase and thus aVect the prenylation of Rho family of small GTPases including Rac and Cdc42. Although the expectation is that statin would inhibit signaling by these GTPases, recent reports indicate that lovastatin can increase expression of Rho and cause an increase in the active form of Rho:GTP [22] . These GTPases exert similar biological activities in cells. However, each of them can also mediate distinct cellular functions through interaction with down-stream eVector proteins in diVerent cell types [23, 24] . Well-documented evidence has also shown that there are extensive cross talk and cooperation between GTPases and other signal transduction pathways. Rac1 and Cdc42 can synergize with Raf to activate ERK [25] [26] [27] . Furthermore, Rac1 cooperates with PI-3 kinase in controlling cell migration and polarity [28] . Interestingly, these small GTPases are found to mediate apoptosis in a wide-range of cell types. Overexpression of active Cdc42 in Jurkat T lymphocytes induces increased ceramide levels, resulting in cell death [29, 30] . Both Rac1 and Cdc42 mediate apoptosis induced by diverse stimuli [31] . It seems that the contribution of Rac1 and Cdc42 to apoptosis is to regulate mainly activation of the JNK pathway [32] [33] [34] .
The eVect of statins on ovarian cancer cell lines is limited to one study showing lovastatin-induced growth inhibition [35] . Here we report that statins induce apoptosis in ovarian cancer cells and inhibit tumor formation in soft agar. Further, we report the novel Wndings that statins can also induce the expression of Rac 1 and Cdc42, and subsequently JNK activity. Our results suggest that statins alone or in combination with other conventional drugs may provide novel therapies for advanced ovarian cancer.
Materials and methods

Reagents and antibodies
Lovastatin (Mevinolin), atorvastatin,farnesylpryophosphate (FPP), geranylgeranylpyrophosphate (GGPP), and SP600125, were from Sigma. Antibodies to RhoA, Rac1, Cdc42, phospho-c-Jun and -actin were from Santa Cruz Biotechnology, Inc. Antibodies were from diVerent companies: Bcl-2 from R&D system (Minneapolis, MN), Bim and Bax from BD Bioscience (San Jose, CA). The antibody to -Actin was purchased from Chemicon (Temecula, CA).
Cell culture and assay for cell viability Hey 1B cells (Dr. Yan Xu, University of Indiana) and Ovcar-3 (ATCC) cells were grown in RPMI-1640 (Cleveland Clinic Foundation Core Facility) supplemented with 10% cosmic calf serum (Hyclone) and antibiotics in a humidiWed atmosphere of 5% CO 2 at 37°C. The viability of Hey 1B cells was determined using the colorimetric CellTiter 96 aqueous Cell Proliferation Assay (MTT) according to the instructions provided by the manufacturer (Promega, Madison, WI). BrieXy, cells (1 £ 10 4 cells per well) were seeded in 96-well plates. One day after seeding, the cells were treated with or without 10 M lovastatin in the presence or absence of 5 M GGPP or 5 M FPP for 48 h. At the end of incubation, 50 l CellTiter 96 Aqueous reagent (40% v/v dilution in 1£ PBS) was added to each well. Plates were incubated at 37°C for 2 h, and absorbance was measured at 490 nm with a 96-well plate reader (model Spectra Max 340; Molecular Devices).
Annexin V assay
Annexin V assay was performed using an Annexin V-FITC/propidium iodine apoptosis detection kit (BD Biosciences, San Jose, CA). BrieXy, cells treated with or without 10 M of lovastatin for 48 h were scraped and centrifuged at 1,000£g for 10 min at 4°C, and washed with ice cold PBS, and then resuspended in 1£ binding buVer provided by the manufacturer at a concentration of 1 £ 10 6 /ml. FITC-Annexin V (5 l) and propidium iodide (5 l) were added to 100 l of the cell suspension and cells were incubated at room temperature for 15 min in the dark. After incubation, 400 l of 1£ binding buVer was added to the cell suspension and cells were analyzed by two-color cytometry using a FACScan™ (Becton Dickinson, Franklin Lake, NJ).
Caspase assays
The activity of caspase 3 in the cells treated with lovastatin was examined by using the Caspase-GloTM 3/7 (Promega, Madison, WI). The assay is based on caspase cleavage of a proluminescent substrate linked with the tetrapeptide DEVD, resulting in the generation of a "glow-type" luminescent signal, produced by luciferase. In brief, cells were treated as described above and cytosolic extracts were prepared by suspension of cell pellets in NP-40 lysis buVer (10 mM TrisHCl, pH 8.0, 5 mM Mg(OAc) 2 , 90 mM KCl, 0.2 mM PMSF, 100 units/ml aprotinin, 10 g/ml leupeptin and 2% NP-40). After centrifugation at 10,000g for 5 min, cell extracts containing 40 g proteins were transferred into a 96-well plate to mix with 50 l of the Caspase-Glo3/7 reagent added. After incubation for 1 h at 37°C, caspase activity was determined by a Xuorescent plate reader (Microtiter Plate Luminometer, Dynex Technologies, Chantilly, VA).
Western blot analysis
After treatments, cells were washed twice with ice-cold phosphate-buVered saline (PBS) and collected with a scraper. Cytoplasmic extracts were prepared by suspension of cell pellets in NP-40 lysis buVer as described above. After centrifugation at 10,000£g in a microcentrifuge at 4°C for 10 min, cell extracts (100 g per sample) were fractionated on SDS-10% polyacrylamide gels and transferred to PVDF membranes (Millipore, Billerica, MA). The membranes were blocked with 5% nonfat milk in PBS containing 0.02% sodium azide and 0.2% (v/v) Tween 20, and incubated with diVerent primary antibodies for 1 h at room temperature. The membranes were then washed with PBS containing 0.2% (v/v) Tween 20 and incubated with speciWc secondary antibodies conjugated with horseradish peroxidase (Cell Signaling, Billerica, MA) for 1 h at room temperature. After washing, these proteins were detected by a chemiluminescence method according to the manufacturer's speciWcation (Pierce, Rockford, IL).
Anchorage-independent cell growth LMP agar (0.6%) in 3 ml of 1£ MEM plus 10% FBS was poured in each well of a six-well plate. After the gel was solidiWed, ovarian cancer cells (6 £ 10 3 ) mixing with 3 ml of 0.35% LMP agar in 1£ MEM plus 10% FBS were laid on the top of previous gel in each well. The plate was incubated in a humidiWed atmosphere of 5% CO 2 at 37°C for 1-2 weeks. The cell colonies were counted and the pictures were taken under Olympus model CKX31 at 100£ magniWcation at day 7 and 14.
Results
Statins induce apoptosis in ovarian cancer cells
Statins are well known for their cholesterol-lowering eVect. Recent studies have revealed that statins inhibit certain cancer cell proliferation, invasion and migration in vitro and in vivo [9] [10] [11] [12] [13] [14] [15] [16] . To determine the direct eVect of statins on ovarian cancer cells, we treated Hey 1B cells, a human ovarian carcinoma cell line, with lovastatin, a member of the statin family, at various doses for 48 h and the lovastatin-induced Hey 1B cell death could be observed by a phase contrast microscope (Fig.1a) . To rule out the possibility that this result was cell line speciWc, Ovcar-3 cells, another ovarian cancer cell line, were treated with lovastatin (Fig.1b) and similar results were obtained. Lovastatin is a product of fungal fermentation in the statin family. To determine, if other statin members have the same eVect on ovarian cancer cells, we treated Hey 1B and Ovcar-3 cells with atorvastatin, a synthetic compound in this family. As shown in Fig. 1a , b, atorvastatin exerted a similar eVect on these ovarian cancer cells. The data indicated that statins at 10 M were suYcient to induce ovarian cancer cell death in vitro.
To quantitatively analyze statin-induced ovarian cancer cell death, the viability of Hey 1B cells in the presence or absence of 10 M lovastatin was analyzed using MTT assay according to the manufacturer's instructions. MTT [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide] is a compound that can be taken up by viable cells and reduced by a mitochondrial dehydrogenase forming a formazan product in living cells. The absorbance of the formazan product at 490 nm is in linear proportion to cell numbers. As shown in Fig. 2 , the cell viability dramatically decreased after Hey 1B cells were treated with lovastatin. Atorvastatin treatment produced a similar result (data not shown).
Inhibition of HMG-CoA reductase by statins results in the depletion of several intermediates products in the mevalonate pathway. These intermediates include farnesypyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP)-isoprenoids that serve as the substrates for the prenylation of Ras and Rho family of small GTPases, respectively. To determine whether supplementation of GGPP or FPP is able to prevent cells from death, Hey 1B cells were co-incubated with 10 M lovastatin and 2.5 M GGPP or FPP. Treatment of Hey 1B cells with GGPP almost completely prevented cell death induced by lovastatin, but FPP only had a partial eVect. These results indicate that blockage of the geranylgeranylation may be more important than prevention of farnesylation for lovastatininduced Hey 1B cell death (Fig. 2) .
To determine whether the decreased viability of Hey 1B cells is due to lovastatin or atorvastatin-induced apoptosis, Annexin V assay was performed. The translocation of membrane phospholipid phosphatidylserine (PS) from the inner to the outer leaXet of the plasma membrane is an early event of cell apoptosis. Annexin V is a 35-36 kD Ca 2+ dependent, phospholipid-binding protein that has a high aYnity for PS. Therefore, FITC-conjugated Annexin V is commonly used to identify apoptotic cells at an early stage. Hey 1B cells were treated with 10 M of lovastatin for 48 h and subjected to Annexin V assay (Fig. 3) (Figs. 2, 3 ), this inhibition occurs at a step subsequent to the externalization of phosphatidylserine. To determine whether lovastatin induces apoptosis immortalized non-cancerous cells, we treated MC3T3-E1, a mouse preosteoblast cell line and WI-38, a human lung Wbroblast cell line, with lovastatin. Although lovastatin was able to induce apoptosis in these cells, a higher concentration (30-50 M) and a prolonged incubation time (72-96 h) were required to achieve the similar level of apoptosis (data not shown). These results are consistent with the previous reports that lovastatin at a higher concentration is needed to induce apoptosis in myeloma plasma cells, smooth muscle cells and endothelial cells [36] [37] [38] , suggesting that ovarian cancer cells may be particularly vulnerable to statin-induced apoptosis.
Statin treatment activates caspase 3
To characterize further the statin-induced apoptosis in ovarian cancer cells, we determined the activity of caspase 3 in Hey 1B cells after treatment with lovastatin. The activity of caspase 3 in the cells treated with lovastatin was examined by using a Caspase-GloTM 3/7 assay kit (Promega). Lovastatin induced the activity of caspase 3 in Hey 1B cells by 3.5-fold. Consistent with our previous results, supplementation of GGPP was able to block caspase 3 activation induced by lovastatin, more eVectively than FPP (Fig. 4) .
Statin treatment enhances the expression of GTPases
Small GTPases act as molecular switches to regulate diverse biochemical functions in all eukaryotic cells through mediating gene expression. Therefore, we investigated the eVect of statins on the expression of certain proteins including the members of the small GTPase family.
Since we had already determined that inhibition of geranyl- geranylation rather than farnesylation plays a role in statininduced apoptosis in ovarian cancer cells, we focused on the Rho family. Intriguingly, we found that lovastatin signiWcantly induced the expression of Rac1 and Cdc42, but not RhoA (Fig. 5a, b) , in a dose and time-dependent manner. Signaling by Rac1 or Cdc42 is known to activate the JNK pathway resulting in phosphorylation of the transcriptional factor c-Jun. Consistent with this, we also determined an increase of p-c-Jun (Fig. 5a, b) . The supplementation of GGPP prevented apoptosis and suppressed the caspase 3 activity in Hey 1B cells induced by statins. This may be due to reduced expression of Rac1 and Cdc42 (Fig. 5c ).
Statin treatment augments the level of Bim in ovarian cancer cells
There are varieties of gene products involved in the process of cell apoptosis. A well-known group of these gene products is the Bcl-2 family. The Bcl-2 family includes both anti-apoptotic and pro-apoptotic members. Signaling by the JNK pathway has been linked to altered expression of several Bcl-2 family members in other systems [39] . To determine if the Bcl-2 family plays a role in statin-induced ovarian cell apoptosis, we examined the expression of Bcl-2, an anti-apoptotic member, in Hey 1B cells treated with lovastatin. As shown in Fig. 6a , there was no signiWcant diVerence in the expression level of the protein in cells treated with lovastatin. We also examined the eVect of lovastatin on the expression of Bax and Bim, pro-apoptotic members of this family. Interestingly, lovastatin signiWcantly induced the expression of Bim, but not Bax in Hey 1B cells in a dose (Fig. 6b ) and time (data not shown) dependent manner, suggesting that Bim may mediate lovastatin-induced ovarian cancer cell apoptosis. Pretreatment of Hey 1 B cells with SP600125, an inhibitor of JNK, markedly decreased lovastatin-induced expression of Bim, conWrming that JNK activation plays a critical role in statin-induced apoptosis in ovarian cancer cells (Fig. 6c) .
Statins inhibit tumor formation in soft agar
Anchorage-independent growth in soft agar is often predictive of tumorigenicity in vivo. Therefore, we performed a soft-agar, colony-formation assay to determine the eVect of statins on tumorigenicity of ovarian cancer cells. In this assay, Hey 1B cells were incubated in soft agar in the presence or absence of lovastatin or atorvastatin. Interestingly, we found that statins signiWcantly inhibited colony-formation of ovarian cancer cells in soft agar. Colony-forming frequencies in soft agar with 10 M of lovastatin or atorvastatin were roughly 10-fold lower than that in the control (Fig. 7a) . The average colony size was dramatically smaller in soft agar containing lovastatin or atorvastatin (data not shown) after incubation for 14 days, suggesting the therapeutic potential of statins in suppression of ovarian tumor growth (Fig. 7b) .
Discussion
Ovarian cancer is often diagnosed at an advanced stage. Thus, although ovarian cancer is the fourth most common cancer in women, it is the leading cause of death among all gynecological malignancies in industrialized countries. The current therapeutic strategy for advance ovarian cancer is a combination of surgery and antimicrotubular chemotherapy. However, a majority of these patients relapses and develops resistance to these chemotherapeutic agents.
The link between the etiology of ovarian cancer and lipid metabolism has been known for decades [40, 41] , yet this knowledge has not been exploited in the search for better treatment strategies. In addition to their role in lowering cholesterol, the statin family of drugs has shown a broad range of functions including suppression of cancer cell growth in vitro and in vivo [9] [10] [11] [12] [13] [14] [15] [16] in many cell types. Surprisingly, the eVect of statins on ovarian cancer is limited to one study documenting lovastatin-induced growth inhibition [35] . In this study, we report that two diVerent statins induce apoptosis in ovarian cancer cells and inhibit growth of ovarian tumors in soft agar. Our results suggest that statins alone, or possibly in combination with other conventional drugs, may represent a novel therapy for advanced ovarian cancer.
Statins are known to inhibit HMG-CoA reductase and thus can inhibit the prenylation of several G-proteins by reducing geranylgeranylpyrophosphate (GGPP) and farnesylpyrophosphate (FPP). Based on this, the expectation would be that statins would inhibit the signaling of prenylated G-proteins. Recently, however, lovastatin was shown to induce the expression of Rho A, B and C in human erythroleukemia cells and to increase the active GTP-bound form of Rho by 3.7 fold [22] . Further, lovastatin did not aVect the prenylation of Ras in erythroleukemia cells, suggesting that inhibition of geranyl-geranylation was more pronounced than inhibition of farnesylation. Neither Rho downstream signaling events nor the status of Rac and cdc 42 were assessed in these cells. Consistent with the Wnding that statins can increase the expression of geranyl-geranylated G-proteins, we have shown that lovastatin treatment increased the expression of both Rac and Cdc 42 in ovarian cancer cells, which could be abolished by inclusion of GGPP but not FPP. However, we did not observe an increase of Rho expression in both Hey 1B and Ovar-3 cells after statin treatment. This distinction is most likely a consequence of cell types. Possible mechanisms whereby the inhibition of prenylation could result in increased expression of prenylated G-proteins would include the possibility that either the unprenylated G-protein aVects the signaling pathway controlling its own expression, or the lack of prenylation impacts this pathway through some other molecules. Consistent with the fact that JNK is a downstream target of Rac and cdc 42 signaling [31, 32] , and that phosphorylation of the transcription factor c-Jun is downstream of JNK activation, we observed an increase in the level of active, phosphorylated c-jun in the ovarian cancer cells under statin treatment. Further investigation revealed that the expression of Bim, a proapoptotic protein, is signiWcantly induced in the cells by statins. These Wndings are consistent with the observation that Bim induction in neurons deprived of NGF is regulated by c-Jun [42] . SP600125 is a competitive inhibitor of ATP binding to JNK and some other kinases [43] . Pretreatment of Hey 1B cells with SP600125 signiWcantly reduced lovastatin-induced expression of Bim, conWrming the role of JNK in induction of Bim in these cells. Our results demonstrating statin-induced apoptosis and inhibition of anchorage independent growth of ovarian cancer cells suggest the validity of investigating the use of statins as a treatment for ovarian cancer. Further, our investigation of the molecular mechanism involved in statin signaling in ovarian cancer cells provides novel potential targets for therapeutic manipulation.
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